Pancreatic Polypeptide, bovine

CAS No. 179986-89-1

Pancreatic Polypeptide, bovine( —— )

Catalog No. M30429 CAS No. 179986-89-1

Agonist at Y4 neuropeptide Y receptors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 826 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote

Biological Information

  • Product Name
    Pancreatic Polypeptide, bovine
  • Note
    Research use only, not for human use.
  • Brief Description
    Agonist at Y4 neuropeptide Y receptors.
  • Description
    Agonist at Y4 neuropeptide Y receptors. (In Vitro):Pancreatic Polypeptide, bovine is an agonist of NPY receptor, with high affinity at NPYR4. Pancreatic Polypeptide (1 μM) does not alter proliferation in BRIN BD11 or 1.1B4 beta-cells, but reverses the decreased cell viability in BRIN BD11 cells induced by streptozotocin. Pancreatic Polypeptide (0.1 nM-1 μM) shows no effect on insulin secretion from isolated mouse islets, and does not affect the membrane potential and (Ca2+)i levels in BRIN BD11 cells at 1 μM. Pancreatic Polypeptide, bovine inhibits secretin- and cholecystokinin-stimulated pancreatic secretion. 125I-Pancreatic Polypeptide, bovine shows no specific binding to pancreatic acini.(In Vivo):Pancreatic Polypeptide (25 nmol/kg bw, i.p.) reduces glucose-stimulated insulin concentrations but shows no effect on acute feeding behaviour in overnight fasted mice. Pancreatic Polypeptide, bovine (BPP; 40 μg/kg) inhibits CCK-33-induced pancreatic protein output during the entire bovine Pancreatic Polypeptide infusion period, but shows no effect on biliary protein output during CCK-33 or CCK-8 infusion.
  • In Vitro
    Pancreatic Polypeptide, bovine is an agonist of NPY receptor, with high affinity at NPYR4. Pancreatic Polypeptide (1 μM) does not alter proliferation in BRIN BD11 or 1.1B4 beta-cells, but reverses the decreased cell viability in BRIN BD11 cells induced by streptozotocin. Pancreatic Polypeptide (0.1 nM-1 μM) shows no effect on insulin secretion from isolated mouse islets, and does not affect the membrane potential and (Ca2+)i levels in BRIN BD11 cells at 1 μM. Pancreatic Polypeptide, bovine inhibits secretin- and cholecystokinin-stimulated pancreatic secretion. 125I-Pancreatic Polypeptide, bovine shows no specific binding to pancreatic acini.
  • In Vivo
    Pancreatic Polypeptide (25 nmol/kg bw, i.p.) reduces glucose-stimulated insulin concentrations but shows no effect on acute feeding behaviour in overnight fasted mice. Pancreatic Polypeptide, bovine (BPP; 40 μg/kg) inhibits CCK-33-induced pancreatic protein output during the entire bovine Pancreatic Polypeptide infusion period, but shows no effect on biliary protein output during CCK-33 or CCK-8 infusion.
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Neuropeptide Y Receptor
  • Recptor
    NPYR4
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    179986-89-1
  • Formula Weight
    4225.78
  • Molecular Formula
    C186H287N53O56S2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    Sequence:Ala-Pro-Leu-Glu-Pro-Glu-Tyr-Pro-Gly-Asp-Asn-Ala-Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Glu-Leu-Arg-Arg-Tyr-Ile-Asn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NH2

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Khan D, et al. Influence of neuropeptide Y and pancreatic polypeptide on islet function and beta-cell survival. Biochim Biophys Acta. 2017 Apr;1861(4):749-758.
molnova catalog
related products
  • Galanin (1-30), huma...

    Galanin (1-30), human is a 30-amino acid neuropeptide, and acts as an agonist of GalR1 and GalR2 receptors, with Kis of both 1 nM. Endogenous peptide with multiple endocrine, metabolic and behavioral effects. Has been shown to have an action on intestinal smooth muscle, insulin and somatostatin release, and synaptic neurotransmission.

  • Velneperit

    Velneperit is potent and selective neuropeptide Y (NPY) Y5 receptor under evaluating for treatment of obesity.

  • Spexin

    Potent galanin receptor 2/3 (GAL2/GAL3) agonist (EC50 values are 45.7 and 112.2 nM, respectively). Exhibits no significant activity at galanin receptor 1. Endogenous satiety-inducing peptide; inhibits long chain fatty acid uptake by adipocytes and decreases food consumption in diet-induced obese mice and rats. Attenuates LH secretion in goldfish. Exhibits anxiolytic effects in vivo.